Related Experiment Video
Updated: Aug 14, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
A New Role of Class A Hepatitis B Virus Capsid Assembly Modulators in Core Protein Dynamics and Covalently Closed
Chunkyu Ko1, Xue Zhou2, Romina Bester3
1Institute of Virology, Technical University of Munich, Helmholtz Munich, Munich, Germany; Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea.
Insights
Hepatitis B virus (HBV) capsid assembly modulators (CAMs) like HAP_R01 disrupt HBV core protein assembly, leading to insoluble protein accumulation and reduced viral replication. This novel mechanism offers a new therapeutic strategy for chronic hepatitis B.
Area of Science:
- Hepatology and Virology
- Molecular Biology
- Drug Discovery
Background:
- Current chronic hepatitis B treatments are rarely curative.
- Capsid assembly modulators (CAMs) target hepatitis B virus (HBV) core protein assembly.
- Class A CAMs (CAM-A) induce abnormal core protein assembly, but their precise mechanism and effect on HBV replication are not fully understood.
Purpose of the Study:
- To investigate the mechanism of action of CAM-A molecule HAP_R01.
- To analyze the effects of HAP_R01 on HBV core protein dynamics, capsid assembly, and viral replication.
- To evaluate the therapeutic potential of HAP_R01 in HBV-infected models.
Main Methods:
- Infection of human liver chimeric mice and HBV-susceptible cells.
- Monitoring of HBV core protein and capsid dynamics under HAP_R01 treatment over four weeks.
- Analysis of HBV virus and protein dynamics, including localization, solubility, and accumulation of core protein.
Main Results:
- HAP_R01 altered HBV core protein's nuclear-cytoplasmic distribution, confirmed in primary human hepatocytes and liver-humanized mice.
- HAP_R01 targeted newly synthesized core protein, affecting assembly, localization, and solubility in a dose- and time-dependent manner.
- Treatment with HAP_R01 reduced HBV covalently closed circular DNA (cccDNA) pool and suppressed HBsAg and HBeAg secretion by inhibiting cccDNA replenishment.
Conclusions:
- HAP_R01, a CAM-A, inhibits HBV replication by disrupting capsid assembly.
- HAP_R01 induces insoluble core protein accumulation in the nucleus, impacting cccDNA pool replenishment.
- Perturbing capsid assembly and inducing core protein aggregation represents a promising therapeutic strategy for chronic hepatitis B.
Background & Aims:
Current treatments of chronic hepatitis B are rarely curative. Capsid assembly modulators target capsid formation by the hepatitis B virus core protein. Class A capsid assembly modulators induce abnormal core protein assembly, but how they affect core protein dynamics and inhibit hepatitis B virus replication is only partially understood.
Methods:
Human liver chimeric mice and hepatitis B virus-susceptible cells were infected to monitor dynamic changes and the fate of core protein and assembled capsids. We analyzed hepatitis B virus and protein dynamics over 4 weeks under treatment of the class A capsid assembly modulator molecule HAP_R01.
Results:
We found an altered nuclear-cytoplasmic distribution of hepatitis B virus core protein upon treatment with HAP_R01. This effect was confirmed in primary human hepatocytes and in hepatitis B virus-infected liver-humanized mice. Mechanism-of-action studies in hepatitis B virus-permissive cells demonstrated that HAP_R01 primarily targets newly synthesized core protein and affects capsid assembly, core protein localization, and solubility in a dose- and time-dependent manner. At 50 nM, HAP_R01 promoted assembly of hepatitis B virus genome-free capsids and nuclear accumulation of core protein. At ≥500 nM, HAP_R01 treatment reduced soluble core protein and capsid levels, but markedly increased insoluble core protein levels, resulting in an overall intracellular accumulation of core protein. Insoluble nuclear agglomerations of core protein were deposited in promyelocytic leukemia nuclear bodies. Treating infected cells for 31 days significantly reduced an established covalently closed circular DNA pool and secreted hepatitis B surface antigen and hepatitis B e antigen levels, by inhibiting covalently closed circular DNA replenishment.
Conclusions:
As an exemplary class A capsid assembly modulator, HAP_R01 inhibits hepatitis B virus genome replication by perturbing capsid assembly and by inducing insoluble core protein accumulation in the nucleus that affects replenishment of the covalently closed circular DNA pool.
More Related Videos
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Retrovirus Life Cycles
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Hepatitis

